Vision RT celebrates 3,000 systems in clinical use worldwide

Founded in 2001 with a mission to make radiation therapy more effective for cancer patients, Vision RT invented Surface Guided Radiation Therapy and remains the market leader in the field.

Today, Vision RT proudly celebrates a significant milestone: more than 3,000 of our systems are actively used in clinics worldwide.

“At Vision RT, we take immense pride in knowing that every SGRT system we develop and deliver represents a step forward in improving cancer care,” said Dr. Norman Smith, CEO.  “Achieving this milestone is a testament to the transformative impact we’ve made with our technology setting a new standard in radiotherapy. Our ultimate goal is for every clinic and every patient around the world to have access to our technology.”

Since the installation of our very first clinical system at Massachusetts General Hospital back in 2004, Vision RT’s SGRT solutions have become a critical part of the new standard of care for radiation therapy. Our systems are in 24 of the top 25 “Best Hospitals for Cancer,” as ranked by U.S. News & World Report.

—

About Vision RT:

Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) which uses camera systems to track surface data, to offer more guidance across every step of the radiotherapy workflow: simulation, planning, treatment and dose visualisation.

We work tirelessly to improve the accuracy, efficiency, safety and comfort of radiation therapy.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 21,000 people.